Screener
Avalo Therapeutics AVTX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $85,382 | $15,858 |
| Short-term investments | 314,894 | 82,478 |
| Prepaid expenses and other current assets | 7,607 | 6,913 |
| Restricted cash, current portion | 49 | 37 |
| Total current assets | 407,932 | 105,286 |
| Long-term investments | 71,878 | — |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's short-term investments?
- Avalo Therapeutics (AVTX) reported short-term investments of $314.89M in Q2 2026.
- How has Avalo Therapeutics's short-term investments changed year-over-year?
- Avalo Therapeutics's short-term investments increased by 343.7% year-over-year, from $70.97M to $314.89M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Avalo Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude